Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 348 results for falls

  1. Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

    Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.

    Technology appraisal guidance
    Last updated
    8 February 2021
    View recommendations

    Sections for TA185

  2. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

    Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin for people with mild chronic hepatitis C.

    Technology appraisal guidance
    Last updated
    27 November 2013
    View recommendations

    Sections for TA106

  3. The consequences and costs of poor transition:- What are the consequences and the costs of young people with ongoing needs not making a transition into adult services, or being poorly supported through the process?

    applicable) Why this is important:- Many young people with ongoing needs fall through the transition gap or disengage with services at...

    Research recommendation
    Published
    21 March 2016

  4. Faller's clinics for the assessment and prevention of falls [ID103]

    Discontinued Reference number: GID-TAG375

    Technology appraisal guidance
    Discontinued

  5. Delirium in long-term care: How common is delirium and what are its adverse outcomes in people in long-term care?

    delirium is a prognostic factor for death, dementia, admission to hospital, falls and other adverse outcomes. The multivariate analysis...

    Research recommendation
    Published
    3 February 2023

  6. AposHealth for knee osteoarthritis (HTG671)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

    HealthTech guidance
    Published
    11 April 2023
    View recommendations

    Sections for HTG671

  7. Falls in older people: assessing risk and prevention (CG161)

    This guideline has been updated and replaced by NICE guideline NG249.

    Clinical guideline
    Published
    12 June 2013

  8. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (TA772)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies.

    Technology appraisal guidance
    Published
    23 February 2022
    View recommendations

    Sections for TA772

  9. Irreversible electroporation for treating liver metastases (IPG445)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

    Interventional procedures guidance
    Published
    23 February 2013
    View recommendations

    Sections for IPG445

  10. FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome (MIB281)

    NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .

    Medtech innovation briefing
    Published
    7 December 2021

  11. Intensive rehabilitation therapies after hip fracture: What is the clinical and cost effectiveness of additional intensive physiotherapy and/or occupational therapy (for example, progressive resistance training) after hip fracture?

    function and health-related quality of life. Outcomes should also include falls. A formal sample size calculation will need to be...

    Research recommendation
    Published
    3 February 2023

  12. Parkinson's disease (QS164)

    This quality standard covers the management of Parkinson’s disease in adults. It does not include treatment of parkinsonism not caused by Parkinson’s disease. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    9 February 2018
    View quality statements

    Sections for QS164

  13. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA178

  14. Ambulatory oxygen to improve outcomes in idiopathic pulmonary fibrosis:- Does ambulatory oxygen improve outcomes in idiopathic pulmonary fibrosis?

    important:- People with idiopathic pulmonary fibrosis frequently demonstrate a fall in oxygen saturation during exercise even though...

    Research recommendation
    Published
    9 June 2015

  15. Early revascularisation strategy for people with angina and multivessel disease:- In people with stable angina and multivessel disease (including left main stem disease) whose symptoms are controlled with optimal drug treatment, would an initial treatment strategy of revascularisation be clinically and cost effective compared with continued drug treatment?

    revascularisation. This disadvantage could be magnified when people who are deemed to fall into very high risk groups (for example, left...

    Research recommendation
    Published
    9 June 2015